Enanta Pharmaceuticals to Present New Data for EDP-235, its 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19, at the 36th International Conference on Antiviral Research

Rhea-AI Summary

Enanta Pharmaceuticals (NASDAQ:ENTA) announced that data for EDP-235, its lead 3CL protease inhibitor for COVID-19, will be presented at the 36th International Conference on Antiviral Research from March 13-17, 2023, in Lyon, France. New clinical data from a Phase 1 study will be showcased, highlighting EDP-235's effectiveness in suppressing viral replication and potentially mitigating viral rebound. Key presentations include an oral presentation on March 15 and several poster presentations on March 14-15. Enanta continues to focus on developing small molecule drugs for viral infections, funded primarily through royalties from hepatitis C products.

Positive

• Presentation of new clinical data for EDP-235 at an international conference could enhance market visibility.
• EDP-235 shows promise in suppressing viral replication and potentially mitigating viral rebound in COVID-19 patients.

Negative

• None.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that data for EDP-235, its lead 3CL protease inhibitor in development as an oral, once-daily treatment for COVID-19, will be presented at the 36th International Conference on Antiviral Research (ICAR) being held March 13-17, 2023 at the Centre De Congres De Lyon (Lyon Convention Center) in Lyon, France.

New clinical data being highlighted include results from a Phase 1 study of EDP-235. Additionally, new preclinical findings regarding EDP-235’s effect on replication and transmission, as well as its potential to mitigate viral rebound, will be presented.

Oral Presentation:
Date/Time: Wednesday, March 15 from 8:30 – 11:30 am Central European Time (CET)
Session Name: Influenza, RSV, and Other Respiratory Viruses – Short Presentations
Abstract ID#: 021
Title: “EDP-235, an Oral 3CL Protease Inhibitor for the Treatment of COVID-19, Suppresses Viral Replication and Spread in SARS-CoV-2-Infected Ferrets”
Presenter Name: Michael Rhodin, Ph.D.

Poster Presentations:
Date/Time: Tuesday, March 14 from 5 – 6pm and Wednesday, March 15 from 2:15 – 3:15 pm CET
Abstract ID#: 523
Title: “EDP-235, a Potent, Once-daily, Oral Antiviral, Demonstrates Excellent Penetration into SARS-CoV-2 Target Tissues, with the Potential for Mitigation of Viral Rebound in COVID-19 Patients”
Presenter: Indy Zhang, Ph.D.

Date/Time: Tuesday, March 14 from 6 – 7pm and Wednesday, March 15 from 12:15 – 1:15 pm CET
Abstract ID#: 524
Title: “EDP-235, an Oral, Once Daily, Ritonavir-Free, 3CL Protease Inhibitor for the Treatment of COVID-19: Results from Phase 1 Study in Healthy Subjects”
Presenter: Guy De La Rosa, M.D.

Date/Time: Tuesday, March 14 from 6 – 7pm and Wednesday, March 15 from 12:15 – 1:15 pm CET
Abstract ID#: 528
Title: “High Throughput Screen to Identify Non-Nucleoside Small Molecule Inhibitors of SARS-CoV-2 RNA-Dependent RNA Polymerase”
Presenter: Tessa Cressey, Ph.D.

Posters will be available to view on the conference platform during the conference. Further information about ICAR 2023 can be found here.

About Enanta Pharmaceuticals, Inc.

Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Enanta’s research and development activities are funded by royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230308005528/en/

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

What data will Enanta Pharmaceuticals present at the ICAR conference in 2023?

Enanta will present data for EDP-235, including results from a Phase 1 study and new preclinical findings.

When is the presentation for EDP-235 scheduled?

The oral presentation for EDP-235 is scheduled for March 15, 2023, from 8:30 to 11:30 am CET.

What are the key findings related to EDP-235?

Key findings include EDP-235's ability to suppress viral replication and its potential to mitigate viral rebound.

What type of drug is EDP-235?

EDP-235 is a 3CL protease inhibitor being developed as an oral, once-daily treatment for COVID-19.

How is Enanta Pharmaceuticals funded?

Enanta's research and development activities are primarily funded by royalties from hepatitis C virus products developed in collaboration with AbbVie.